Gujarat Themis Biosyn Limited has initiated arbitration proceedings against Optimus Drugs Private Limited to recover damages following the termination of a supply agreement. The company claims the termination occurred contrary to the agreed terms and has approached a Learned Sole Arbitrator to resolve the dispute. The total claim amounts to ₹113.8 crore, covering break fees, interest, and financial losses incurred due to the breach of contract.

Details of the dispute

Optimus Drugs allegedly breached the mandatory "Take-or-Pay" minimum purchase obligations outlined in the agreement. Consequently, Gujarat Themis Biosyn is seeking specific recoveries from the respondent. The company asserts that the termination was unjustified and has resulted in significant financial impact, necessitating legal intervention to enforce the terms of the original contract.

Breakdown of claims

The arbitration filing details several components of the financial claim being pursued by Gujarat Themis Biosyn. The company is seeking restitution for specific breaches and the resultant monetary damages.

Financial implications and regulatory filing

Gujarat Themis Biosyn stated that since it has initiated the arbitration proceeding claiming recovery and damages, it does not anticipate any adverse financial implications arising from penalties. The disclosure was made to the BSE Limited and National Stock Exchange of India Limited on June 26, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted by Vineet Gawankar, Company Secretary & Compliance Officer.

Gujarat Themis Biosyn Limited has expanded its international footprint by incorporating a step-down subsidiary, Themis Biosyn Private Limited, in Ireland on June 16, 2026. The newly formed entity operates within the pharmaceutical industry and holds a share capital of 100 Euro. This strategic move aims to bolster the company's presence in the European market.

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that Themis Biosyn Private Limited is a wholly owned subsidiary of Themis Biosyn Ireland Private Limited, which holds 100% of the shareholding.

Details regarding the incorporation were submitted to the BSE Limited and the National Stock Exchange of India Limited. The company clarified that the transaction does not fall under related party transactions, and no specific governmental or regulatory approvals were required for this incorporation.

The following table outlines the key details of the newly incorporated subsidiary:

The Board of Directors of Gujarat Themis Biosyn approved the strategic expansion, with the intimation signed by Dinesh S. Patel, Chairman & Director. The company received the business registration extract for the new entity on the same date as its incorporation.